BioCentury | Aug 13, 2012
Clinical News

NVB302: Phase I data

...presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco in September. Novacta Biosystems Ltd....
BioCentury | Nov 7, 2011
Clinical News

NVB302: Phase I started

...Novacta began a Phase I trial to evaluate oral NVB302 in healthy volunteers. Novacta Biosystems Ltd. , Welwyn...
BioCentury | Sep 26, 2011
Company News

Silence Therapeutics management update

...LSE:SLN), London, U.K. Business: Cancer, Renal, Ophthalmic Hired: Tony Sedgwick as CBO, formerly CEO of Novacta Biosystems Ltd....
BioCentury | Jul 13, 2009
Financial News

Novacta completes venture financing

Novacta Biosystems Ltd. , Welwyn Garden City, U.K. Business: Infectious, Biomanufacturing Date completed: 7/6/09 Type: Venture financing Raised: £13.1 million ($21.1 million) Investors: Celtic Pharma Holdings Advisors; existing investors WIR Staff...
BioCentury | Jul 13, 2009
Company News

Novacta board of directors update

Novacta Biosystems Ltd. , Welwyn Garden City, U.K. Business: Infectious, Biomanufacturing Appointed: Andy Richards as chairman; Richard Garraway and Bob Milsted, partners at Celtic Pharma Holdings Advisors LLP Retiring: Andrew Sandham as chairman WIR Staff Infectious...
BioCentury | Jul 7, 2009
Financial News

Novacta raises L13.1 million

...in an equity financing led by new investor Celtic Pharma. Undisclosed existing investors also participated. Novacta's...
...class of antibiotic peptide found in bacteria. Celtic's Richard Garraway and Bob Milsted will join Novacta's...
BioCentury | Jul 6, 2009
Finance

Ebb & Flow

...the first fund. The firm was to announce it will acquire a 60% stake in Novacta Biosystems Ltd....
...on and dealt with accordingly," he said. Celtic would always expect to have board representation. Novacta...
BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Infectious disease

...steps could include further optimization of the mutagenesis methodology to produce more potent lead compounds. Novacta...
...unavailable Appleyard, A. et al. Cell; published online May 28, 2009; doi:10.1016/j.chembiol.2009.03.011 Contact: Jesus Cortes, Novacta...
BioCentury | Nov 24, 2008
Company News

Novacta Ltd., Ministry of Defence deal

...The ministry will evaluate Novacta's lantibiotics for antiviral use. Novacta's Novacta Therapeutics unit is developing NVB302...
...NVB302 , a preclinical lantibiotic, to treat Clostridium difficile infection. Financial terms were not disclosed. Novacta...
BioCentury | Oct 13, 2008
Company News

Novacta, The Wellcome Trust infectious news

...Clostridium difficile infection. Novacta received the first tranche earlier this year (see BioCentury, Jan. 21). Novacta Biosystems Ltd....
Items per page:
1 - 10 of 12
BioCentury | Aug 13, 2012
Clinical News

NVB302: Phase I data

...presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco in September. Novacta Biosystems Ltd....
BioCentury | Nov 7, 2011
Clinical News

NVB302: Phase I started

...Novacta began a Phase I trial to evaluate oral NVB302 in healthy volunteers. Novacta Biosystems Ltd. , Welwyn...
BioCentury | Sep 26, 2011
Company News

Silence Therapeutics management update

...LSE:SLN), London, U.K. Business: Cancer, Renal, Ophthalmic Hired: Tony Sedgwick as CBO, formerly CEO of Novacta Biosystems Ltd....
BioCentury | Jul 13, 2009
Financial News

Novacta completes venture financing

Novacta Biosystems Ltd. , Welwyn Garden City, U.K. Business: Infectious, Biomanufacturing Date completed: 7/6/09 Type: Venture financing Raised: £13.1 million ($21.1 million) Investors: Celtic Pharma Holdings Advisors; existing investors WIR Staff...
BioCentury | Jul 13, 2009
Company News

Novacta board of directors update

Novacta Biosystems Ltd. , Welwyn Garden City, U.K. Business: Infectious, Biomanufacturing Appointed: Andy Richards as chairman; Richard Garraway and Bob Milsted, partners at Celtic Pharma Holdings Advisors LLP Retiring: Andrew Sandham as chairman WIR Staff Infectious...
BioCentury | Jul 7, 2009
Financial News

Novacta raises L13.1 million

...in an equity financing led by new investor Celtic Pharma. Undisclosed existing investors also participated. Novacta's...
...class of antibiotic peptide found in bacteria. Celtic's Richard Garraway and Bob Milsted will join Novacta's...
BioCentury | Jul 6, 2009
Finance

Ebb & Flow

...the first fund. The firm was to announce it will acquire a 60% stake in Novacta Biosystems Ltd....
...on and dealt with accordingly," he said. Celtic would always expect to have board representation. Novacta...
BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Infectious disease

...steps could include further optimization of the mutagenesis methodology to produce more potent lead compounds. Novacta...
...unavailable Appleyard, A. et al. Cell; published online May 28, 2009; doi:10.1016/j.chembiol.2009.03.011 Contact: Jesus Cortes, Novacta...
BioCentury | Nov 24, 2008
Company News

Novacta Ltd., Ministry of Defence deal

...The ministry will evaluate Novacta's lantibiotics for antiviral use. Novacta's Novacta Therapeutics unit is developing NVB302...
...NVB302 , a preclinical lantibiotic, to treat Clostridium difficile infection. Financial terms were not disclosed. Novacta...
BioCentury | Oct 13, 2008
Company News

Novacta, The Wellcome Trust infectious news

...Clostridium difficile infection. Novacta received the first tranche earlier this year (see BioCentury, Jan. 21). Novacta Biosystems Ltd....
Items per page:
1 - 10 of 12